DelveInsight’s, “HR Positive/ HER2 Negative Breast Cancer Pipeline Insights 2023” report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape. It covers the HR Positive/ HER2 Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HR Positive/ HER2 Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the HR Positive/ HER2 Negative Breast Cancer Pipeline Report

• DelveInsight’s HR Positive/ HER2 Negative Breast Cancer pipeline report depicts a robust space with 50+ active players working to develop 53+ pipeline therapies for HR Positive/ HER2 Negative Breast Cancer treatment.
• The leading companies working in the HR Positive/ HER2 Negative Breast Cancer Market include Regor Therapeuics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co. Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche, and others.
• Promising HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies in the various stages of development include CX-2009, CX-072, Dato-DXd, Capecitabine, Gemcitabine, OP-1250, Ribociclib, Alpelisib, Palbociclib 125mg, Cyclophosphamide, Doxorubicin, and others.
• December 2023: AstraZeneca announced a study of Phase 3 clinical trials for AZD9833, Anastrozole, and Letrozole. The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
• December 2023: Hofmann-La Roche announced a study of Phase 3 clinical trials for Inavolisib, Fulvestrant and Alpelisib. This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based therapy.
• December 2023: Novartis Pharmaceuticals announced a study of Phase 3 clinical trials for Ribociclib, Letrozole, Alpelisib and Fulvestrant. The purpose of this clinical trial is to study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole and, in patients with a PIK3CA mutation, on second-line treatment with alpelisib plus fulvestrant.

 

Request a sample and discover the recent advances in HR Positive/ HER2 Negative Breast Cancer Treatment Drugs @ HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report

 

In the HR Positive/ HER2 Negative Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, HR Positive/ HER2 Negative Breast Cancer NDA approvals (if any), and product development activities comprising the technology, HR Positive/ HER2 Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

HR Positive/ HER2 Negative Breast Cancer Overview

A breast cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and progesterone, which suggests the cancer cells receive signals from these hormones that promote their growth. Cancer tissue is also tested for HER-2 proteins, or receptors, that help control the growth and repair of breast cells in which HER-2-negative breast cancers, have cells that contain little to no HER-2 protein, so they tend to grow more slowly and have a better outlook than HER-2-positive cancers The breast cancer subtype HR+/HER2- is the most common subtype with an age-adjusted rate of 87.4 new cases per 100,000 women, based on 2015–2019 cases.

 

Find out more about HR Positive/ HER2 Negative Breast Cancer Therapeutics Assessment @ HR Positive/ HER2 Negative Breast Cancer Preclinical and Discovery Stage Products

 

HR Positive/ HER2 Negative Breast Cancer Emerging Drugs Profile

• Camizestrant: AstraZeneca
• Dato-DXd: Daiichi Sankyo, Inc.
• CX-2009: CytomX Therapeutics
• RGT-419B: Regor Therapeutics

 

HR Positive/ HER2 Negative Breast Cancer Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing therapies for HR Positive/ HER2 Negative Breast Cancer. The HR Positive/ HER2 Negative Breast Cancer companies which have their HR Positive/ HER2 Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

 

DelveInsight’s HR Positive/ HER2 Negative Breast Cancer pipeline report covers around 53+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

HR Positive/ HER2 Negative Breast Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Learn more about the emerging HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies @ HR Positive/ HER2 Negative Breast Cancer Clinical Trials Assessment

 

Scope of the HR Positive/ HER2 Negative Breast Cancer Pipeline Report

• Coverage- Global
• HR Positive/ HER2 Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HR Positive/ HER2 Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• HR Positive/ HER2 Negative Breast Cancer Companies- Regor Therapeuics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co. Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche, and others.
• HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies- CX-2009, CX-072, Dato-DXd, Capecitabine, Gemcitabine, OP-1250, Ribociclib, Alpelisib, Palbociclib 125mg, Cyclophosphamide, Doxorubicin, and others

 

Dive deep into rich insights for new drugs for HR Positive/ HER2 Negative Breast Cancer Treatment, Visit @ HR Positive/ HER2 Negative Breast Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. HR Positive/ HER2 Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HR Positive/ HER2 Negative Breast Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Dato-DXd: Daiichi Sankyo, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CX-2009: CytomX Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RGT-419B: Regor Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HR Positive/ HER2 Negative Breast Cancer- Unmet Needs
21. HR Positive/ HER2 Negative Breast Cancer- Market Drivers and Barriers
22. Appendix

 

For further information on the HR Positive/ HER2 Negative Breast Cancer Pipeline therapeutics, reach out to HR Positive/ HER2 Negative Breast Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market